Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents.
Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019 08; 50(4):373-385.